Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Claims20
A method of delivering a transgene to the skin of a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
- a) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding the transgene;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 herpes simplex virus gene;
- wherein the pharmaceutical composition is topically or transdermally administered to the subject;
- and
- wherein the pharmaceutical composition is administered to one or more areas of the subject affected by a wound, disorder, or disease of the skin.
A method of delivering a transgene to the skin of a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
- a) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding the transgene;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the recombinant herpes simplex virus genome comprises an inactivating mutation in one or both copies of the ICP4 herpes simplex virus gene;
- wherein the pharmaceutical composition comprises an ointment, paste, cream, suspension, emulsion, fatty ointment, gel, powder, lotion, solution, spray, patch, or microneedle array;
- and
- wherein pharmaceutical composition is administered to one or more areas of the subject affected by a wound, disorder, or disease of the skin.
Dependencies are inferred from the claim text.